<DOC>
	<DOCNO>NCT01886248</DOCNO>
	<brief_summary>To evaluate efficacy safety AT-III treatment patient hepatic veno-occlusive disease follow hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Antithrombin-III Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>1 . Patients hepatic venoocclusive disease hematopoietic stem cell transplantation . The following criterion use . 1 . Two follow Serum total bilirubin &gt; 2.0 mg/dL Hepatomegaly right upper quadrant pain liver origin Unexplained weight gain &gt; 2 % baseline fluid accumulation 2 . Patients pathologic diagnosis . 2 . Patients informed consent 1 . Pregnant nursing woman . 2 . Malignant nonmalignant illness uncontrolled whose control may jeopardize complication study therapy . 3 . Psychiatric disorder would preclude compliance . 4 . Patients , opinion investigator , may able comply safety monitoring requirement study . 5 . History anaphylactic reaction study drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>hepatic veno-occlusive disease hematopoietic stem cell transplantation</keyword>
</DOC>